| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
2-(4-isopropylthiazol-2-yl)-7-methoxy-8-methylquinolin-4-ol has been shown to have anti-hepatitis C virus (HCV) activity. It targets the HCV replication machinery, potentially through inhibition of viral enzymes or interference with viral RNA replication. The quinoline-thiazole scaffold provides specific interactions with viral targets.
|
|---|---|
| ln Vitro |
In vitro studies have demonstrated that this compound exhibits anti-HCV activity. It has been evaluated for its ability to inhibit HCV replication in cell-based assays. The compound shows activity against HCV, making it a potential lead for antiviral drug development.
|
| ln Vivo |
In vivo activity data are limited. As a synthetic quinoline derivative with anti-HCV activity, it may have been evaluated in animal models for antiviral efficacy. Further studies are needed to fully characterize its in vivo pharmacokinetics and efficacy.
|
| Enzyme Assay |
For enzyme inhibition assays, the compound is dissolved in DMSO and diluted in assay buffer. The target enzyme (e.g., HCV protease or polymerase) is incubated with varying concentrations (0.1-100 µM) at 25-37°C for 30-60 minutes. Enzyme activity is measured using appropriate detection methods. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
For cell-based studies, HCV-infected cell lines are cultured in DMEM or RPMI-1640 with 10% FBS at 37°C in 5% CO₂. Cells are treated with the compound at 0.1-100 µM for 24-72 hours. Viral replication is measured by qRT-PCR or immunoassay. Cytotoxicity is assessed using MTT or CellTiter-Glo assays.
|
| Animal Protocol |
For in vivo studies, the compound is formulated in suitable vehicles and administered orally or intraperitoneally to HCV-infected animal models at 10-100 mg/kg. Efficacy is evaluated by measuring viral load reduction. Pharmacokinetic studies determine compound exposure and half-life. Toxicity is monitored by body weight and clinical observations.
|
| ADME/Pharmacokinetics |
2-(4-isopropylthiazol-2-yl)-7-methoxy-8-methylquinolin-4-ol has a molecular weight of 314.40 g/mol and a molecular formula of C₁₇H₁₈N₂O₂S. It has a PubChem CID of 53393377. It is typically stored as a solid at room temperature. Purity is typically ≥98%. It is soluble in organic solvents such as DMSO.
|
| Toxicity/Toxicokinetics |
Acute toxicity data are limited. Standard laboratory safety practices should be followed. The compound may cause skin and eye irritation upon contact. Proper personal protective equipment should be used. Long-term toxicity studies have not been reported.
|
| Additional Infomation |
2-(4-isopropylthiazol-2-yl)-7-methoxy-8-methylquinolin-4-ol is a synthetic quinoline derivative also known as 7MMQ. It has anti-hepatitis C virus (HCV) activity. It is a research chemical and is not an FDA-approved drug.
|
| Molecular Formula |
C17H18N2O2S
|
|---|---|
| Molecular Weight |
314.4
|
| Exact Mass |
314.109
|
| CAS # |
923289-21-8
|
| PubChem CID |
53393377
|
| Appearance |
Typically exists as solids at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
518.0±60.0 °C at 760 mmHg
|
| Flash Point |
267.1±32.9 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.635
|
| LogP |
6.12
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
22
|
| Complexity |
466
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C(C=CC2=C1NC(=CC2=O)C3=NC(=CS3)C(C)C)OC
|
| InChi Key |
LPPRPUJPNUYIKH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H18N2O2S/c1-9(2)13-8-22-17(19-13)12-7-14(20)11-5-6-15(21-4)10(3)16(11)18-12/h5-9H,1-4H3,(H,18,20)
|
| Chemical Name |
7-methoxy-8-methyl-2-(4-propan-2-yl-1,3-thiazol-2-yl)-1H-quinolin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1807 mL | 15.9033 mL | 31.8066 mL | |
| 5 mM | 0.6361 mL | 3.1807 mL | 6.3613 mL | |
| 10 mM | 0.3181 mL | 1.5903 mL | 3.1807 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
